ArticleMicrosystems & nanoengineering2025
Fully automated in vivo screening system for multi-organ imaging and pharmaceutical evaluation.
Article in Microsystems & nanoengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Real-time, cross-modal genotype mapping of free-movingScience advances · 2026Article
- An Anesthesia-Free Pharmacological Assay for Zebrafish Heart Failure Models Using a Microfluidic Platform.Biomedicines · 2026Article
- ZeCardioAI: combining zebrafish, AI, and xAI for an in-depth cardiac phenotyping platform.Briefings in bioinformatics · 2026Article
- Pharmaceutical 3D Printing for Psychiatric Medications: Advanced Innovations in Taste Masking and Personalized Oral Drug Delivery.Pharmaceutical research · 2025Review
- Zebrafish as a Versatile Model for Cardiovascular Research: Peering into the Heart of the Matter.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advancements in screening technologies employing small organisms have enabled deep profiling of compounds in vivo. However, current strategies for phenotyping of behaving animals, such as zebrafish, typically involve tedious manipulations. Here, we develop and validate a fully automated in vivo screening system (AISS) that integrates microfluidic technology and computer-vision-based control methods to enable rapid evaluation of biological responses of non-anesthetized zebrafish to molecular gradients. Via precise fluidic control, the AISS allows automatic loading, encapsulation, transportation and immobilization of single-larva in droplets for multi-organ imaging and chemical gradients generation inaccessible in previous systems. Using this platform, we examine the cardiac sensitivity of an antipsychotic drug with multiple concentration gradients, and reveal dramatic diversity and complexity in the accurate chemical regulation of cardiac functions in vivo. This proposed system expands the arsenal of tools available for in vivo screening and facilitates comprehensive profiling of pharmaceuticals.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.